HRP20231464T1 - Protutijela protiv tnf-alfa i njihovi funkcionalni fragmenti - Google Patents
Protutijela protiv tnf-alfa i njihovi funkcionalni fragmenti Download PDFInfo
- Publication number
- HRP20231464T1 HRP20231464T1 HRP20231464TT HRP20231464T HRP20231464T1 HR P20231464 T1 HRP20231464 T1 HR P20231464T1 HR P20231464T T HRP20231464T T HR P20231464TT HR P20231464 T HRP20231464 T HR P20231464T HR P20231464 T1 HRP20231464 T1 HR P20231464T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- functional fragment
- accordance
- inflammatory disorder
- nucleic acid
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims 13
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 229940027941 immunoglobulin g Drugs 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000005095 gastrointestinal system Anatomy 0.000 claims 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
- 102000057041 human TNF Human genes 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Claims (13)
1. Protutijelo, ili njegov funkcionalni fragment, koji se može specifično vezati na ljudski čimbenik tumorske nekroze alfa (TNFα), naznačen time što navedeno protutijelo, ili njegov funkcionalni fragment, sadrži (i) VL domenu koja ima aminokiselinski slijed kao što je prikazan u SEQ ID NO:14, i (ii) VH domenu koja ima aminokiselinski slijed kao što je prikazan u SEQ ID NO:13, te što se specifično vezanje odnosi na sposobnost razlikovanja protutijela, ili njegovog fragmenta, između ljudskog TNFα i ljudskog TNFβ.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je imunoglobulin G (IgG).
3. Protutijelo u skladu s patentnim zahtjevom 2, naznačeno time što je podrazred IgG IgG1.
4. Protutijelo u skladu s patentnim zahtjevom 2 ili 3, naznačeno time što svaki laki lanac IgG ima aminokiselinski slijed kao što je prikazan u SEQ ID NO:52.
5. Nukleinska kiselina, naznačena time što kodira protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od prethodnih patentnih zahtjeva.
6. Vektor ili plazmid, naznačeni time što sadrže nukleinsku kiselinu u skladu s patentnim zahtjevom 5.
7. Stanica, naznačena time što sadrži nukleinsku kiselinu u skladu s patentnim zahtjevom 5 ili vektor ili plazmid u skladu s patentnim zahtjevom 6.
8. Postupak priprave protutijela, ili njegovog funkcionalnog fragmenta, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se sastoji u uzgoj stanice u skladu s patentnim zahtjevom 7 u mediju u uvjetima koji omogućuju eksprimiranje nukleinske kiseline koja kodira protutijelo, ili njegov funkcionalni fragment, i prikupljanju protutijela, ili njegovog funkcionalnog fragmenta, iz stanica ili iz medija.
9. Farmaceutski pripravak, naznačen time što sadrži protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, te izborno farmaceutski prihvatljivi nosač i/ili pomoćno sredstvo.
10. Protutijelo, ili njegov funkcionalni fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što je namijenjeno upotrebi u postupku liječenja upalnog poremećaja.
11. Protutijelo, ili njegov funkcionalni fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 10, naznačeno time što je navedeni upalni poremećaj upalni poremećaj gastrointestinalnog sustava.
12. Protutijelo, ili njegov funkcionalni fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što je navedeni upalni poremećaj gastrointestinalnog sustava upalna crijevna bolest.
13. Protutijelo, ili njegov funkcionalni fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 11 ili 12, naznačeno time što je navedeni upalni poremećaj gastrointestinalnog sustava Crohnova bolest ili ulcerozni kolitis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160907.8A EP3219726B1 (en) | 2016-03-17 | 2016-03-17 | Anti-tnf alpha-antibodies and functional fragments thereof |
| EP17710748.9A EP3430043B1 (en) | 2016-03-17 | 2017-03-16 | Anti-tnfalpha-antibodies and functional fragments thereof |
| PCT/EP2017/056237 WO2017158092A1 (en) | 2016-03-17 | 2017-03-16 | Anti-tnfalpha-antibodies and functional fragments thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231464T1 true HRP20231464T1 (hr) | 2024-03-01 |
Family
ID=55542576
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231464TT HRP20231464T1 (hr) | 2016-03-17 | 2017-03-16 | Protutijela protiv tnf-alfa i njihovi funkcionalni fragmenti |
| HRP20210123TT HRP20210123T1 (hr) | 2016-03-17 | 2021-01-22 | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210123TT HRP20210123T1 (hr) | 2016-03-17 | 2021-01-22 | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US11459383B2 (hr) |
| EP (3) | EP3219726B1 (hr) |
| JP (2) | JP7129398B2 (hr) |
| KR (2) | KR102470235B1 (hr) |
| CN (1) | CN109071650B (hr) |
| AR (1) | AR107917A1 (hr) |
| AU (1) | AU2017235387A1 (hr) |
| BR (1) | BR112018016667A2 (hr) |
| CA (1) | CA3011784C (hr) |
| CL (1) | CL2018002649A1 (hr) |
| CO (1) | CO2018009783A2 (hr) |
| CR (1) | CR20180448A (hr) |
| CY (1) | CY1123784T1 (hr) |
| DK (2) | DK3219726T3 (hr) |
| EA (1) | EA039760B1 (hr) |
| ES (2) | ES2836349T3 (hr) |
| FI (1) | FI3430043T3 (hr) |
| GE (1) | GEP20217307B (hr) |
| HR (2) | HRP20231464T1 (hr) |
| HU (2) | HUE052773T2 (hr) |
| IL (1) | IL261031A (hr) |
| JO (2) | JOP20170064B1 (hr) |
| LT (2) | LT3219726T (hr) |
| MA (1) | MA43717B1 (hr) |
| MD (1) | MD3430043T2 (hr) |
| MX (1) | MX2018011258A (hr) |
| MY (1) | MY194041A (hr) |
| PH (1) | PH12018501907A1 (hr) |
| PL (2) | PL3219726T3 (hr) |
| PT (2) | PT3219726T (hr) |
| RS (2) | RS61374B1 (hr) |
| SA (1) | SA518400027B1 (hr) |
| SG (1) | SG11201807062RA (hr) |
| SI (2) | SI3219726T1 (hr) |
| TN (1) | TN2018000298A1 (hr) |
| TW (2) | TWI784945B (hr) |
| UY (1) | UY37157A (hr) |
| WO (1) | WO2017158092A1 (hr) |
| ZA (4) | ZA202108599B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108884156B (zh) | 2016-03-17 | 2021-10-01 | 努玛创新有限公司 | 抗TNFα抗体及其功能片段 |
| PT3219727T (pt) | 2016-03-17 | 2021-01-21 | Tillotts Pharma Ag | Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos |
| EP3430042B1 (en) | 2016-03-17 | 2023-05-24 | Numab Innovation AG | Anti-tnfalpha-antibodies and functional fragments thereof |
| EP3456737B1 (en) * | 2017-09-19 | 2024-02-14 | Tillotts Pharma Ag | Antibody variants |
| EP3456736B1 (en) * | 2017-09-19 | 2021-04-07 | Tillotts Pharma Ag | Antibody variants |
| EP3456738A1 (en) * | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Antibody variants |
| WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| SI9720020B (en) * | 1996-02-09 | 2001-12-31 | Basf Ag | Human antibodies that bind human TNF alpha |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| CN100387621C (zh) | 1997-04-14 | 2008-05-14 | 麦可麦脱股份公司 | 抗人抗原受体的新的生产方法及其用途 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2301254T3 (es) | 1998-11-18 | 2008-06-16 | Genentech, Inc. | Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales. |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| NZ563580A (en) | 2005-06-07 | 2010-09-30 | Esbatech An Alcon Biomedical R | Stable and soluble antibodies inhibiting TNFaplha |
| KR101882352B1 (ko) | 2008-06-25 | 2018-07-26 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
| KR20190133077A (ko) | 2008-06-25 | 2019-11-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 저해하는 안정한 가용성 항체 |
| CN102088958A (zh) | 2008-07-10 | 2011-06-08 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 用于大分子的增强的递送的方法和组合物 |
| KR20150038556A (ko) * | 2010-04-07 | 2015-04-08 | 애브비 인코포레이티드 | ＴＮＦ-α 결합 단백질 |
| CA2805572A1 (en) | 2010-07-16 | 2012-01-19 | Martin Hegen | Modified single domain antigen binding molecules and uses thereof |
| KR20130062366A (ko) | 2010-09-30 | 2013-06-12 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 인간화 항 TNF α 항체 및 그의 항원 결합 단편 (FAB) 및 용도 |
| IL293477A (en) | 2013-06-26 | 2022-08-01 | Numab Therapeutics AG | New frameworks for antibodies |
| US9416197B2 (en) * | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
| MX2016012479A (es) * | 2014-03-26 | 2017-05-23 | Cell Medica Switzerland Ag | Miembros de unión al factor de necrosis tumoral (tnf) alfa. |
| CN108884156B (zh) | 2016-03-17 | 2021-10-01 | 努玛创新有限公司 | 抗TNFα抗体及其功能片段 |
| PT3219727T (pt) | 2016-03-17 | 2021-01-21 | Tillotts Pharma Ag | Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos |
| EP3430042B1 (en) | 2016-03-17 | 2023-05-24 | Numab Innovation AG | Anti-tnfalpha-antibodies and functional fragments thereof |
-
2016
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/en active Active
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
-
2017
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active IP Right Grant
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Application Discontinuation
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 DK DK17710748.9T patent/DK3430043T3/da active
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/en active Active
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 CA CA3011784A patent/CA3011784C/en active Active
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 AU AU2017235387A patent/AU2017235387A1/en active Pending
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 EP EP23192170.1A patent/EP4275745A3/en active Pending
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-16 BR BR112018016667A patent/BR112018016667A2/pt unknown
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/en active Application Filing
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
-
2018
- 2018-08-07 IL IL261031A patent/IL261031A/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
-
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/ar unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
-
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US20230272059A1/en active Pending
- 2022-10-03 US US17/958,759 patent/US20230279091A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231464T1 (hr) | Protutijela protiv tnf-alfa i njihovi funkcionalni fragmenti | |
| HRP20210120T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti | |
| HRP20201505T1 (hr) | Široko neutralizirajuća anti-hiv protutijela | |
| HRP20201259T1 (hr) | Protutijela protiv ox40 i njihova upotreba | |
| HRP20230060T1 (hr) | Antitijela protiv ox40 i njihova primjena | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| HRP20220891T1 (hr) | Protutijela, primjene i postupci | |
| JP2017029157A5 (hr) | ||
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20210122T1 (hr) | Protutijela usmjerena protiv programirane smrti-1 (pd-1) | |
| HRP20201031T1 (hr) | Anti-ctla-4 protutijela i postupci njihove upotrebe | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| HRP20210364T1 (hr) | Anti-gitr antitijela i postupci za njihovu primjenu | |
| HRP20210375T1 (hr) | Virus ljudske imunodeficijencije neutraliziranja antitijela i postupci njegova korištenja | |
| HRP20201852T1 (hr) | Optimizacija antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| JP2017163973A5 (hr) | ||
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| HRP20211820T1 (hr) | Anti-tim-3 protutijela i pripravci | |
| JP2017529067A5 (hr) |